An Open Label Study of the Effect of First Line Combination Treatment With Avastin and Docetaxel on Disease Response in Patients With Metastatic Breast Cancer.

Trial Profile

An Open Label Study of the Effect of First Line Combination Treatment With Avastin and Docetaxel on Disease Response in Patients With Metastatic Breast Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Docetaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms PRIMADOS
  • Sponsors Roche
  • Most Recent Events

    • 23 May 2013 Planned End Date changed from 1 Feb 2014 to 1 Nov 2013 as reported by ClinicalTrials.gov.
    • 27 Aug 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 03 Mar 2010 Planned number of patients changed from 88 to 100 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top